Graham
Biotech

Elevidys fallout hasn't dented Roche's hopes for gene therapies

Uncertainty around Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the Swiss company’s head of pharma told Fierce.
James Waldron Jul 25, 2025 8:30am
FDA Pathways Offer Faster Track for Oncology Drug Development

FDA Pathways Offer Faster Track for Oncology Drug Development

Jul 21, 2025 8:00am
Fingers crossed

Boehringer 'crossing fingers' ahead of 2 key FDA approvals

Jul 24, 2025 3:00am
Open farm gate leading into agricultural landscape

Lilly links up with Gate in $856M biobucks deal

Jul 24, 2025 2:32pm
hiring new hire appointment executive

BMS names AZ's Cristian Massacesi as new chief medical officer

Jul 25, 2025 9:26am
parachute sunset paragliding chutes

Ikena and Inmagene choose combined CEO—Chutes & Ladders

Jul 25, 2025 8:30am
More News

Memo pushes kidney drug to phase 3 despite primary endpoint miss

Jul 25, 2025 5:30am
Fierce Pharma

FDA eyeing study requirements to confirm Elevidys safety: report

Jul 24, 2025 3:12pm

Brandon Capital raises $290M life sciences fund, its largest yet

Jul 24, 2025 3:05pm

Trinity Biotech outlines plans for wearable CGM sensor platform

Jul 24, 2025 12:30pm